Charles River Labs sees acquisition of CRO services accretive to FY14 EPS by 10c Charles River Laboratories International announced that it has completed the previously announced acquisition of the CRO services division of Galapagos NV, which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization, or CRO, with integrated in vitro and in vivo capabilities from target discovery through preclinical development. The acquisition is expected to add approximately 6% to Charles Riverís net sales in 2014. It is also expected to be accretive to non-GAAP EPS in 2014 by approximately 10c. Items excluded from non-GAAP earnings per share are expected to include all deal-related costs including amortization of intangible assets.